| Nome |
# |
|
Implementation of value-based pricing for medicines, file e31e10d3-f045-31fb-e053-1705fe0a5b99
|
1.202
|
|
La spesa sanitaria: composizione ed evoluzione, file e31e10d3-a83e-31fb-e053-1705fe0a5b99
|
1.016
|
|
Digital Twins in healthcare: is it the beginning of a new era of evidence-based medicine? A critical review, file 7d29e364-cddc-4d1d-9c13-7ad6dbcc8246
|
488
|
|
Programma Nazionale di HTA per dispositivi medici: prove tecniche di implementazione, file e31e10d3-1065-31fb-e053-1705fe0a5b99
|
422
|
|
Il confronto dei sistemi sanitari in una prospettiva internazionale, file e31e10d2-2a91-31fb-e053-1705fe0a5b99
|
231
|
|
Digitalizzazione nelle tecnologie per la salute: impatto sui livelli di governo del SSN, file 902988a5-e71e-4da3-af92-c3fa4978d5fa
|
203
|
|
L'acquisto di farmaci in Italia: l'effetto di approcci selettivi, file e31e10d3-a840-31fb-e053-1705fe0a5b99
|
201
|
|
Prezzi di riferimento per dispositivi medici: criticità, vantaggi e approcci, file e31e10d3-8f97-31fb-e053-1705fe0a5b99
|
188
|
|
Establishing a national HTA program for medical devices in Italy: overhauling a fragmented system to ensure value and equal access to new medical technologies, file e31e10d4-4fb9-31fb-e053-1705fe0a5b99
|
178
|
|
Dinamiche economiche e performance del settore dei dispositivi medici in Italia, file e31e10d3-e3f9-31fb-e053-1705fe0a5b99
|
177
|
|
The value of hearing aids for the Italian NHS: a cost-utility analysis, file 856584b2-8524-43d1-aedc-e066b4448ff5
|
140
|
|
I settori contigui alla sanità: struttura e performance delle imprese farmaceutiche, di dispositivi medici e delle farmacie in Italia, file e31e10d2-3344-31fb-e053-1705fe0a5b99
|
130
|
|
L'adozione dell'innovazione tecnologica da parte degli ospedali italiani: un'analisi dei fattori endogeni, file e31e10d2-2d59-31fb-e053-1705fe0a5b99
|
121
|
|
Il confronto dei sistemi sanitari in una prospettiva internazionale, file e31e10d2-2d49-31fb-e053-1705fe0a5b99
|
118
|
|
La spesa sanitaria: composizione ed evoluzione, file e31e10d3-01d9-31fb-e053-1705fe0a5b99
|
99
|
|
Politiche del farmaco ed impatto sulla spesa: gli effetti di quindici anni di decentramento nel SSN, con un focus sull’adozione di forme alternative di distribuzione dei farmaci, file e31e10d2-fcc9-31fb-e053-1705fe0a5b99
|
95
|
|
Il governo dell'assistenza farmaceutica in Italia: possibili traiettorie di cambiamento, file e31e10d3-0735-31fb-e053-1705fe0a5b99
|
93
|
|
Mobile health divide between clinicians and patients in cancer care: results from a cross-sectional international survey, file e31e10d3-a8e9-31fb-e053-1705fe0a5b99
|
85
|
|
La spesa sanitaria: composizione ed evoluzione, file e31e10d3-00c8-31fb-e053-1705fe0a5b99
|
74
|
|
Prezzi di riferimento per dispositivi medici: criticità, vantaggi e approcci, file e31e10d3-8f03-31fb-e053-1705fe0a5b99
|
74
|
|
The future of Funds for Innovative Medicines: results from a Delphi Study, file e31e10d4-60f9-31fb-e053-1705fe0a5b99
|
66
|
|
The cost of patients with chronic kidney failure before dialysis: results from the IRIDE observational study, file e31e10d3-afd9-31fb-e053-1705fe0a5b99
|
65
|
|
Il confronto dei sistemi sanitari in una prospettiva internazionale, file e31e10d2-abc1-31fb-e053-1705fe0a5b99
|
60
|
|
La spesa sanitaria: composizione ed evoluzione, file e31e10d2-2d56-31fb-e053-1705fe0a5b99
|
57
|
|
Cost-utility analysis of esketamine for patients with treatment resistant depression in Italy, file 0adf408d-bb15-41cb-b679-d10564c186c1
|
56
|
|
La spesa sanitaria: composizione ed evoluzione, file e31e10d2-23ed-31fb-e053-1705fe0a5b99
|
56
|
|
Social economic costs, health-related quality of life and disability in patients with Cri Du Chat syndrome, file e31e10d4-05cb-31fb-e053-1705fe0a5b99
|
48
|
|
Il confronto dei sistemi sanitari in una prospettiva internazionale, file e31e10d3-01dc-31fb-e053-1705fe0a5b99
|
34
|
|
The invisible costs of obstructive sleep apnea (OSA): systematic review and cost-of-illness analysis, file b1ce3a42-c0f9-42fa-ad1a-5a8e88e5f066
|
32
|
|
Individual and team performanc: issues around the role of attributes and relationships among peers, file c1b5dbe7-d17f-45ee-8759-f8c503694615
|
31
|
|
La spesa sanitaria: composizione ed evoluzione, file e31e10d3-ec8d-31fb-e053-1705fe0a5b99
|
30
|
|
Il confronto dei sistemi sanitari in una prospettiva internazionale, file e31e10d3-01d2-31fb-e053-1705fe0a5b99
|
29
|
|
La spesa sanitaria: composizione ed evoluzione, file e31e10d3-092d-31fb-e053-1705fe0a5b99
|
28
|
|
Reflections on the importance of cost of illness analysis in rare diseases: a proposal, file e31e10d4-3e00-31fb-e053-1705fe0a5b99
|
16
|
|
Early access programs for medicines: comparative analysis among France, Italy, Spain, and UK and focus on the Italian case, file 74e9fba6-acc1-4e61-80ca-ba5cc97a5b6e
|
13
|
|
Cost-minimization analysis to support the HTA of Radiofrequency Echographic Multi Spectrometry (REMS) in the diagnosis of osteoporosis, file 522fb8a9-d43e-48b3-ba3b-37e3b35eaf1a
|
12
|
|
Cost-effectiveness and net monetary benefit of durvalumab consolidation therapy versus no consolidation therapy after chemoradiotherapy in stage III non–small cell lung cancer in the Italian National Health Service, file e31e10d3-e3f3-31fb-e053-1705fe0a5b99
|
12
|
|
Cost-benefit analysis in health care: the case of bariatric surgery compared with diet, file e31e10d3-d276-31fb-e053-1705fe0a5b99
|
9
|
|
Economic impact of a more extensive use of FENO testing on the Italian population with asthma, file 61ad1d24-f96d-4ece-84e7-9b332ce92230
|
8
|
|
The social burden and quality of life of patients with haemophilia in Italy, file e31e10d2-319e-31fb-e053-1705fe0a5b99
|
6
|
|
Cost-effectiveness analysis of HRD testing for previously treated patients with advanced ovarian cancer in Italy, file a7c7ce65-19da-48d8-9af1-49aa5906602e
|
5
|
|
Report n. 42 OSFAR (Osservatorio Farmaci), file 5c55be94-59c7-4640-8c57-75da4ddee62a
|
4
|
|
A meta-analysis of MitraClip combined with medical therapy versus medical therapy alone for treatment of mitral regurgitation in heart failure patients, file e31e10d3-5590-31fb-e053-1705fe0a5b99
|
4
|
|
Programmi di early access dei farmaci e managed entry agreement in Italia: i risultati di un Focus Group (programmi di early access e managed entry agreement), file e31e10d4-9b7f-31fb-e053-1705fe0a5b99
|
4
|
|
Cost-utility analysis of esketamine for patients with treatment resistant depression in Italy, file ad058f52-fb1a-4363-bd6a-a1b10f6fea75
|
3
|
|
Cost-utility analysis of esketamine for patients with treatment resistant depression in Italy, file c9a26da7-e6a1-4ff4-963c-a099a092f86a
|
3
|
|
PDTA per la chirurgia bariatrica: l'esperienza di 6 centri italiani, file e31e10d2-1df1-31fb-e053-1705fe0a5b99
|
3
|
|
La spesa sanitaria: composizione ed evoluzione, file e31e10d2-23d5-31fb-e053-1705fe0a5b99
|
3
|
|
La spesa sanitaria: composizione ed evoluzione, file e31e10d2-23ec-31fb-e053-1705fe0a5b99
|
3
|
|
Comparative effectiveness of Mitraclip plus medical therapy versus medical therapy alone in high-risk surgical patients: a comprehensive review, file e31e10d2-5938-31fb-e053-1705fe0a5b99
|
3
|
|
Real-world cost effectiveness of MitraClip combined with medical therapy versus medical therapy alone in patients with moderate or severe mitral regurgitation, file e31e10d2-7d67-31fb-e053-1705fe0a5b99
|
3
|
|
When peers count: the effects on integrated type II diabetes care of communication within general practitioner-only subgroups in interprofessional primary care teams, file e31e10d2-afa2-31fb-e053-1705fe0a5b99
|
3
|
|
A value-based revolution in health care: perspectives, challenges, and emerging approaches to defining and measuring the value of health care technologies, file e31e10d3-d653-31fb-e053-1705fe0a5b99
|
3
|
|
Cost-effectiveness and net monetary benefit of Olaparib maintenance therapy versus no maintenance therapy after first-line platinum-based chemotherapy in newly diagnosed advanced BRCA1/2-mutated ovarian cancer in the Italian National Health Service, file e31e10d4-3d6c-31fb-e053-1705fe0a5b99
|
3
|
|
Cost-effectiveness analysis of pressure-controlled intermittent coronary sinus occlusion in elective percutaneous coronary intervention, file 0c30151d-a574-439c-8c5d-f06a81cc7bcd
|
2
|
|
The impact of generic reference pricing in Italy, a decade on, file e31e10d2-20ab-31fb-e053-1705fe0a5b99
|
2
|
|
Il governo regionale dell'assistenza farmaceutica e il suo impatto sulla spesa, file e31e10d2-246e-31fb-e053-1705fe0a5b99
|
2
|
|
De innovatione: the concept of innovation for medical technologies and its implications for healthcare policy-making, file e31e10d2-564c-31fb-e053-1705fe0a5b99
|
2
|
|
The impact of generic reference pricing in Italy, a decade on, file e31e10d2-58a4-31fb-e053-1705fe0a5b99
|
2
|
|
Social/economic costs and health-related quality of life in patients with Duchenne muscular dystrophy in Europe, file e31e10d2-827f-31fb-e053-1705fe0a5b99
|
2
|
|
Social/economic costs and quality of life in patients with haemophilia in Europe, file e31e10d2-839b-31fb-e053-1705fe0a5b99
|
2
|
|
The impact of HTA and procurement practices on the selection and prices of medical devices, file e31e10d2-9f15-31fb-e053-1705fe0a5b99
|
2
|
|
La rendicontazione e la remunerazione dei farmaci. Finalità, struttura e gestione del File F in nove Regioni italiane, file e31e10d2-d040-31fb-e053-1705fe0a5b99
|
2
|
|
Cost-effectiveness of the coronary sinus Reducer and its impact on the healthcare burden of refractory angina patients, file e31e10d3-cce0-31fb-e053-1705fe0a5b99
|
2
|
|
Percutaneous mitral valve repair vs. stand-alone medical therapy in patients with functional mitral regurgitation and heart failure, file e31e10d3-cd61-31fb-e053-1705fe0a5b99
|
2
|
|
Cost per responder of Adalimumab biosimilars MSB11022 and ABP 501 versus the originator and methotrexate in chronic plaque psoriasis, file 094ff056-6e45-4db9-be14-367b317c1841
|
1
|
|
Cost per responder of Adalimumab biosimilars MSB11022 and ABP 501 versus the originator and methotrexate in chronic plaque psoriasis, file c652030f-d0a4-46c0-947a-2b9224365e53
|
1
|
|
The impact of generic reference pricing in Italy, a decade on, file e31e10d2-20a9-31fb-e053-1705fe0a5b99
|
1
|
|
Market access management by pharmaceutical companies in a complex environment: the Italian case study, file e31e10d2-22cd-31fb-e053-1705fe0a5b99
|
1
|
|
L'attività sperimentale sui dispositivi medici, file e31e10d2-22d2-31fb-e053-1705fe0a5b99
|
1
|
|
L'attività sperimentale sui dispositivi medici, file e31e10d2-22d3-31fb-e053-1705fe0a5b99
|
1
|
|
Il settore dei dispositivi medici in Italia. L’impatto delle politiche pubbliche sulle performance delle imprese, file e31e10d2-23cd-31fb-e053-1705fe0a5b99
|
1
|
|
La spesa sanitaria: composizione ed evoluzione, file e31e10d2-23ee-31fb-e053-1705fe0a5b99
|
1
|
|
Multi-professional primary care units: what affects the
clinical performance of Italian general practitioners?, file e31e10d2-2f28-31fb-e053-1705fe0a5b99
|
1
|
|
What type of clinical evidence is needed to assess medical devices?, file e31e10d2-79be-31fb-e053-1705fe0a5b99
|
1
|
| Totale |
6.082 |